| pubmed-article:16465399 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16465399 | lifeskim:mentions | umls-concept:C0021494 | lld:lifeskim |
| pubmed-article:16465399 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:16465399 | lifeskim:mentions | umls-concept:C0023890 | lld:lifeskim |
| pubmed-article:16465399 | lifeskim:mentions | umls-concept:C0015127 | lld:lifeskim |
| pubmed-article:16465399 | lifeskim:mentions | umls-concept:C0001925 | lld:lifeskim |
| pubmed-article:16465399 | lifeskim:mentions | umls-concept:C1314792 | lld:lifeskim |
| pubmed-article:16465399 | lifeskim:mentions | umls-concept:C0205341 | lld:lifeskim |
| pubmed-article:16465399 | lifeskim:mentions | umls-concept:C1447107 | lld:lifeskim |
| pubmed-article:16465399 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:16465399 | pubmed:dateCreated | 2006-2-8 | lld:pubmed |
| pubmed-article:16465399 | pubmed:abstractText | Hepatocyte growth factor (HGF) is a promising agent for the treatment of liver cirrhosis because of its mitogenic and anti-fibrotic effects. We investigated the effect of recombinant human HGF (rh-HGF) on cirrhosis development; its pharmacokinetics and nephrotoxicity in rats with liver cirrhosis induced by 4-week treatment with dimethylnitrosamine (DMN). rh-HGF (0.3 mg/kg) was intravenously administered to rats once a day for 4 weeks in parallel with DMN treatment or twice a day for the last 2 weeks of DMN treatment. Repeated doses of rh-HGF increased the liver weight and serum albumin, and reduced serum ALT. The development of hepatic fibrosis was inhibited more efficiently by extended low-dose treatment with rh-HGF. In cirrhotic rats, serum levels of rh-HGF increased and clearance was decreased, leading to an increase in the area under the plasma-concentration time curve and a decrease in the steady-state volume of distribution. Repeated doses of rh-HGF led to increased urinary albumin excretion, but no rh-HGF-treated animals developed increased serum creatinine levels. Urinary albumin excretion returned to baseline after the cessation of rh-HGF. These results suggest that extended treatment with rh-HGF is required for the attenuation of cirrhosis, and repeated doses of rh-HGF cause adverse effects in extra-hepatic organs. These issues must be resolved before the widespread application of rh-HGF in the treatment of liver cirrhosis. | lld:pubmed |
| pubmed-article:16465399 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16465399 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16465399 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16465399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16465399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16465399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16465399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16465399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16465399 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16465399 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:16465399 | pubmed:issn | 1107-3756 | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:NagataKenjiK | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:TsubouchiHiro... | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:KatsuraToshiy... | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:InuiKen-IchiK | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:KimIldeokI | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:UtoHirofumiH | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:IdoAkioA | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:MoriuchiAkihi... | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:HasuikeSatoru... | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:KodamaMayumiM | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:NumataMasatsu... | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:KusumotoKazun... | lld:pubmed |
| pubmed-article:16465399 | pubmed:author | pubmed-author:TakahamaYukaY | lld:pubmed |
| pubmed-article:16465399 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16465399 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:16465399 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16465399 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16465399 | pubmed:pagination | 503-9 | lld:pubmed |
| pubmed-article:16465399 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:meshHeading | pubmed-meshheading:16465399... | lld:pubmed |
| pubmed-article:16465399 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16465399 | pubmed:articleTitle | Repeated intravenous injection of recombinant human hepatocyte growth factor ameliorates liver cirrhosis but causes albuminuria in rats. | lld:pubmed |
| pubmed-article:16465399 | pubmed:affiliation | Department of Internal Medicine II, Faculty of Medicine, University of Miyazaki, Japan. | lld:pubmed |
| pubmed-article:16465399 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16465399 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16465399 | lld:pubmed |
